Intrathecal production and secretion of vascular endothelial growth factor during cryptococcal meningitis

Journal of Infectious Diseases

Volumn 190, Issue 7, 2004, Pages 1310-1317

  Coenjaerts, Frank E J ^a,b   Van Der Flier, Michiel ^b,c   Mwinzi, Pauline N M ^a,b   Brouwer, Annemarie E ^d,e,g   Scharringa, Jelle ^a,b   Chaka, Wendy S ^a,h   Aarts, Marieke ^b,f   Rajanuwong, Adul ^f   Van De Vijver, David A ^a   Harrison, Tom S ^g   Hoepelman, Andy I M ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Sappasitthiprasong Hospital   (Thailand)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; FUNGUS ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VASCULOTROPIN;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL STIMULATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; FUNGAL MENINGITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACRANIAL PRESSURE; MAJOR CLINICAL STUDY; MONOCYTE; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; SERUM; T LYMPHOCYTE;

ADULT; ANTIGEN PRESENTATION; ANTIGENS, FUNGAL; BLOOD-BRAIN BARRIER; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; LEUKOCYTES; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4644335016     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/423849     Document Type: Article

References (53)

1. Kwon-Chung KJ, Sorrell TC, Dromer F, Fung E, Levitz SM. Cryptococcosis: clinical and biological aspects. Med Mycol 2000; 38(Suppl 1): 205-13.
2. Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985, 103:533-8.
3. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710-8.
4. Brown HC, Chau TT, Mai NT, et al. Blood-brain barrier function in cerebral malaria and CNS infections in Vietnam. Neurology 2000; 55: 104-11.
5. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998; 140:947-59.
6. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280:C1358-66.
7. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997; 79:233-69.
8. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172:1535-45.
9. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGE Oncogene 1999; 18:5356-62.
10. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152:4149-56.
11. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180:341-6.
12. Matsuyama W, Hashiguchi T, Umehara F, et al. Expression of vascular endothelial growth factor in tuberculous meningitis. J Neurol Sci 2001; 186:75-9.
13. Heiss JD, Papavassiliou E, Merrill MJ, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats: involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996; 98:1400-8.
14. van der Flier M, Stockhammer G, Vonk GJ, et al. Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain. J Infect Dis 2001; 183:149-53.
15. van Bruggen N, Thibodeaux H, Palmer JT, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 1999; 104:1613-20.
16. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106:829-38.
17. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996; 270:H1803-11.
18. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994; 267:H1948-54.
19. Inoue T, Kibata K, Suzuki M, Nakamura S, Motoda R, Orita K. Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16. FEBS Lett 2000; 469:14-8.
20. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997; 90:4153-61.
21. Perez-Ruiz M, Ros J, Morales-Ruiz M, et al. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology 1999; 29:1057-63.
22. Xiong M, Elson G, Legarda D, Leibovich SJ. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol 1998; 153:587-98.
23. Williams B, Quinn-Baker A, Gallacher B. Serum and platelet-derived growth factor-induced expression of vascular permeability factor mRNA by human vascular smooth muscle cells in vitro. Clin Sci (Lond) 1995; 88: 141-7.
24. van der Flier M, Coenjaerts F, Kimpen JL, Hoepelman AM, Geelen SP. Streptococcus pneumoniae induces the secretion of vascular endothelial growth factor by human neutrophils. Infect Immun 2000; 68:4792-4.
25. Cherniak R, Morris LC, Anderson BC, Meyer SA. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect Immun 1991; 59:59-64.
26. Coenjaerts FE, Walenkamp AM, Mwinzi PN, et al. Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization. J Immunol 2001; 167:3988-95.
27. Walenkamp AM, Verheul AF, Scharringa J, Hoepelman IM. Pulmonary surfactant protein A binds to Cryptococcus neoformans without promoting phagocytosis. Eur J Clin Invest 1999; 29:83-92.
28. Boyum A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968; 97:77-89.
29. Lipovsky MM, Gekker G, Anderson WR, Molitor TW, Peterson PK, Hoepelman AI. Phagocytosis of nonopsonized Cryptococcus neoformans by swine microglia involves CD14 receptors. Clin Immunol Immunopathol 1997; 84:208-11.
30. Andersson LM, Hagberg L, Fuchs D, Svennerholm B, Gisslen M. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals: correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol 2001; 7:542-7.
31. Eng RH, Bishburg E, Smith SM, Kapila R. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 1986; 81:19-23.
32. Vecchiarelli A, Pietrella D, Dottorini M, et al. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol 1994; 98:217-23.
33. Vecchiarelli A, Dottorini M, Pietrella D, et al. Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans in fection. Am J Respir Cell Mol Biol 1994; 11:130-7.
34. Delfino D, Cianci L, Migliardo M, et al. Tumor necrosis factor-inducing activities of Cryptococcus neoformans components. Infect Immun 1996; 64:5199-204 (erratum: Infect Immun 1997; 65:1991).
35. Delfino D, Cianci L, Migliardo M, et al. Tumor necrosis factor-inducing activities of Cryptococcus neoformans components. Infect Immun 1996; 64:5199-204 (erratum: Infect Immun 1997; 65:1991).
36. Davies SF, Clifford DP, Hoidal JR, Repine JE. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. J Infect Dis 1982; 145:870-4.
37. Kozel TR, Pfrommer GS, Guerlain AS, Highison BA, Highison GJ. Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev Infect Dis 1988; 10(Suppl 2):S436-9.
38. Kozel TR. Opsonization and phagocytosis of Cryptococcus neoformans. Arch Med Res 1993; 24:211-8.
39. Chaka W, Verheul AF, Vaishnav VV, et al. Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect Immun 1997; 65:272-8.
40. Delfino D, Cianci L, Lupis E, et al. Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components. Infect Immun 1997; 65:2454-6.
41. Pietrella D, Cherniak R, Strappini C, et al. Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun 2001; 69:2808-14.
42. Walenkamp AM, Chaka WS, Verheul AF, et al. Cryptococcus neoformans and its cell wall components induce similar cytokine profiles in human peripheral blood mononuclear cells despite differences in structure. FEMS Immunol Med Microbiol 1999; 26:309-18.
43. Kawakami K, Tohyama M, Qifeng X, Saito A. Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effects of interleukin-12. Infect Immun 1997; 65:1307-12.
44. Lee SC, Kress Y, Zhao ML, Dickson DW, Casadevall A. Cryptococcus neoformans survive and replicate in human microglia. Lab Invest 1995; 73:871-9.
45. Lee SC, Dickson DW, Brosnan CF, Casadevall A. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J Exp Med 1994; 180:365-9.
46. Aguirre K, Miller S. MHC class II-positive perivascular microglial cells mediate resistance to Cryptococcus neoformans brain infection. Glia 2002; 39:184-8.
47. Ascherl G, Hohenadl C, Schatz O, et al. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. Blood 1999; 93:4232-41.
48. Vecchiarelli A, Retini C, Pietrella D, Monari C, Kozel TR. T lymphocyte and monocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. Eur J Immunol 2000; 30:1385-93.
49. Matsuyama W, Kubota R, Hashiguchi T, et al. Purified protein derivative of tuberculin upregulates the expression of vascular endothelial growth factor in T lymphocytes in vitro. Immunology 2002; 106:96-101.
50. Villadangos JA. Presentation of antigens by MHC class II molecules: getting the most out of them. Mol Immunol 2001; 38:329-46.
51. + human lymphocytes are activated and proliferate in response to Cryptococcus neoformans. Immunology 1997; 92:194-200.
52. Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol 1996; 27:839-47.
53. Nag S, Takahashi JL, Kilty DW. Role of vascular endothelial growth factor in blood-brain barrier breakdown and angiogenesis in brain trauma. J Neuropathol Exp Neurol 1997; 56:912-21.